Obesity Clinical Trial
Official title:
Prevention Strategies for Adolescents at Risk of Diabetes - A Randomised Controlled Trial of an Interactive Family-based Lifestyle Programme
NCT number | NCT02845791 |
Other study ID # | 65436 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | October 2017 |
Verified date | January 2019 |
Source | University Hospitals, Leicester |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To investigate whether the interactive family based lifestyle programme leads to behaviour change at 6 months with the primary outcome being increased levels of moderate to vigorous physical activity (MVPA).
Status | Completed |
Enrollment | 318 |
Est. completion date | October 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 14 Years |
Eligibility |
Inclusion Criteria: Parents/guardians will answer questions in the eligibility questionnaire about their child and family health history. Participants will be invited to participate if they are 12-14 years old inclusive (12 years 0 days to 14 years 354 days old) and are identified as having the following risk factors for development of Type 2 Diabetes (which will be identified from the eligibility questionnaire): BMI > 95th percentile for age and gender OR BMI > 85th percentile PLUS one other from the following list: - Family history of Diabetes (first degree relative). - Non-white ethnicity. - Watching TV/play computer games for more than 2 hours a day (self-report). - Sugar intake more than 1.5 cans (or 532 ml) of fizzy pop/fruit juice per day (self-report). Exclusion Criteria: Young people will not be eligible for participation in the study if they are outside the age range of interest (<11 years and 364 days or >14 years and 1 day), have an existing diagnosis of Type 1 or Type 2 Diabetes, < 85th percentile. Young people will also be excluded if they themselves do not provide written assent or their parent/guardian does not provide written consent. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | University Hospitals of Leicester | Leicester |
Lead Sponsor | Collaborator |
---|---|
University Hospitals, Leicester | Alexander Technological Educational Institute, Thessaloniki, Greece, Associacao Protectora dos Diabeticos de Portugal, Basque Government Department of Public Health, Diabetes Centre of Paediatrics P&A, Health Department of the Alto/Bajo Deba, Spain, Primary Care Centre Egia, San Sebastian, Spain, Technische Universität Dresden, The Algarve Regional Health Administration, University of Leicester, University of Leipzig |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary endpoint is to detect a change in objectively measured MVPA of 10 minutes per day within the intervention group at 6 months. | Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. | 6 months post baseline | |
Secondary | An increase in total volume of physical activity | Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. | 3 and 6 months | |
Secondary | An increase in the proportion meeting MVPA guidelines | Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. | 3 and 6 months | |
Secondary | Reduction in time spent sedentary | Participating children and adults will be asked to wear the wrist worn GENEActiv accelerometer (ActivInsights, Kimbolton, Cambridgeshire, UK) continuously for up to 8 days. | 3 and 6 months | |
Secondary | Change in physical activity levels | Self reported - questionnaire | 3 and 6 months | |
Secondary | Reduction in Body mass index percentile (BMI) | Body mass will be measured to the nearest 0.1kg and height will be measured to the nearest 0.1 cm using a clinically approved bioelectrical impedance scale and a portable stadiometer, respectively. BMI will be calculated as weight/height2 and will be converted to a BMI percentile based on WHO growth charts | 3 and 6 months | |
Secondary | Change in healthy food provision and parenting practices for healthy food | As parents are active participants in the intervention The Investigators will also query their knowledge and attitudes towards healthy eating and physical activity. | 3 and 6 months | |
Secondary | Improvement in diet composition | The Investigators will query the nutrition habits of participants to investigate any changes in the behaviours targeted in the workshops. A food frequency questionnaire (FFQ) taken from the ISCOLE study that was adapted from the HBSC Study will be used to query the consumption of 23 food categories in a "usual" week. The Investigators will also query breakfast consumption for weekdays and weekends. The Investigators have also created ad hoc questions on other intervention targets of snacking behaviours, fruit and vegetable intake and fizzy drink consumption. This ad hoc method has been used in other international multi-site studies. | 3 and 6 months | |
Secondary | Improvement in knowledge of physical activity and nutrition | The physical activity questionnaire for adolescents (PAQ-A) [62] will be used to assess the Types and context of physical activity in order to investigate changes in the Types of sports/exercise/activities the participating child may participate in (information which is not available from the accelerometer or the majority of other validated self-report questionnaires). This questionnaire requests responses for the last 7 days by asking participants to check a list of activities for frequency of participation. This questionnaire has received support from an expert panel and has also high validity against objective measures and moderate reliability. | 3 and 6 months | |
Secondary | Improvement in HbA1c | Biochemical measures (Child only) - HbA1c | 3 and 6 months | |
Secondary | Improvement in Triglycerides | Biochemical measures (Child only) - Triglycerides | 3 and 6 months | |
Secondary | Improvement in Glucose | Biochemical measures (Child only) - Glucose | 3 and 6 months | |
Secondary | Improvement in HDL-C | Biochemical measures (Child only) HDL-C | 3 and 6 months | |
Secondary | Improvement in Total Cholesterol | Biochemical measures (Child only) -Total cholesterol will be measured using a point-of-care testing (POCT) and LDL-C will be calculated. | 3 and 6 months | |
Secondary | Improvement in cardio-metabolic variables | Biochemical measures (Child only) - Capillary blood samples will be taken from each child using the finger prick method. The CardioChek® system will be used as the POCT method. The CardioChek® system is a portable hand held device that requires between 15 to 40 µL capillary sample from a finger-stick for each test. The CardioChek® system is certified by the Cholesterol Reference Method Laboratory Network (CRMLN) and National Cholesterol Education Program (NCEP), is FDA-cleared, CE-marked, internationally registered, and is CLIA-waived by the Centers for Medicare & Medicaid Services, USA. | 3 and 6 months | |
Secondary | Blood Pressure (Child) | Arterial blood pressure will be measured using an automated sphygmomanometer with an appropriate sized cuff while the patient is seated, and having rested quietly for 5 minutes. Three measurements will be obtained for blood pressure and an average of the last two will be used in any analysis. | 3 and 6 months | |
Secondary | Blood Pressure (Parent(s)/guardian(s)) | Arterial blood pressure will be measured using an automated sphygmomanometer with an appropriate sized cuff while the patient is seated, and having rested quietly for 5 minutes. Three measurements will be obtained for blood pressure and an average of the last two will be used in any analysis. | 3 and 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |